Vertex reported quarterly revenues of $3.19 billion, exceeding expectations, with continued strength in its core therapies. The company announced positive Phase 4 data for its non-opioid pain drug JOURNAVX, showing effective pain management and high rates of opioid-free recovery. Its pipeline, including candidates for kidney disease, is gaining investor attention. However, the CEO and CMO recently sold company stock under pre-approved plans, and a key innovation executive is retiring.